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Abstract  
Background: Specialist weight management services provide a treatment option for severe 
obesity. 
Objective: To review the characteristics, impact and practice implications of specialist 
weight management services for adults in the UK. 
Design: Systematic review. EMBASE, MEDLINE and PsycINFO were searched from 
January 2005 to March 2016 with supplementary searches. 
Inclusion criteria: Adults with a body mass index of ≥40kg/m2, or ≥35kg/m2 with comorbidity 
or ≥30 kg/m2 with type 2 diabetes. Any study of multicomponent interventions, in any UK or 
Ireland setting, delivered by a specialist multidisciplinary team.   
Results: 14 studies in a variety of settings were included: 1 randomised controlled trial; 3 
controlled and 10 observational studies. Mean baseline body mass index and age ranged 
from 40-54 kg/m2 and 40-58 years. The studies were heterogeneous making comparisons of 
service characteristics difficult. Multidisciplinary team composition and eligibility criteria 
varied; dropout rates were high (43-62%). Statistically significant reduction in mean body 
mass index over time ranged from -1.4 kg/m2 to -3.1 kg/m2 and mean weight changes 
ranged from -2.2 kg to -12.4 kg. Completers achieving at least 5% reduction of initial body 
weight ranged from 32%-51%. There was evidence for improved outcomes in diabetics. 
Conclusions: Specialist weight management services can demonstrate clinically significant 
weight loss and have an important role in supporting adults to manage severe and often 
complex forms of obesity. This review highlights important variations in provision and 
strongly indicates the need for further research into effective approaches to support severely 
obese adults. 
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Introduction 
England, typical of many high income countries, is facing an obesity epidemic with around a 
quarter of adults currently classed as obese1. In the UK obesity is managed on a tiered 
pathway: Tier 1: universal prevention services; Tier 2: lifestyle weight management 
interventions; Tier 3: specialist multidisciplinary weight management service (WMS); Tier 4: 
bariatric surgery2,3,4. Tier 3 services are recommended for adults with a body mass index (BMI) 
of ≥40kg/m2, or ≥35kg/m2 with co-morbidities, or ≥30kg/m2 with type 2 diabetes mellitus 
(T2DM); who have been unsuccessful in losing weight through standard multicomponent 
lifestyle interventions (Tier 2). Since this review was conducted the National Institute for Health 
and Care Excellence (NICE) have published further guidance5 on referral criteria for Tier 3 
services: adults with a BMI of 30 or more for whom Tier 2 interventions have been 
unsuccessful. 
An NHS England and Public Health England Working Group provided a working example of a 
Tier 3 service. A Tier 3 service is comprised of a multidisciplinary team (MDT) of specialists, 
led by a clinician and typically including: a physician (consultant or GP with a special interest); 
specialist nurse; specialist dietitian; psychologist or psychiatrist; and physiotherapist/physical 
activity specialist/physiology3. Clinical and commissioning guidance exist to support the 
delivery of Tier 3 services6,7 and provide an evaluation framework8. 
Clinical commissioning groups and local authorities commission Tier 3 services in England, 
but there is no universal provision, with a number of areas not offering any or little in the way 
of specialist services3,7,9,10. A recent publication on the rewards and challenges of setting up a 
Tier 3 adult WMS in primary care called for more robust evaluation of Tier 3 services to 
demonstrate cost-effectiveness to the NHS11. 
Hassan et al12 recently published a review examining the effectiveness of lifestyle 
interventions for adults with severe obesity. The review included 17 RCTs of at least 12-weeks 
duration; participants receiving the lifestyle intervention had a greater decrease in weight than 
participants in the control group for all studies (1.0–11.5 kg). The review was the first 
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systematic review to focus on lifestyle interventions for the severely obese and identified one 
RCT that exclusively targeted adults with a mean BMI >40 kg/m2 (the other study participants 
had a comorbidity associated with excess weight and a mean baseline BMI between 35 kg/m2 
and 38 kg/m2). In addition, quality of life was only reported in two RCTs. None of the RCTs 
were set in the UK.  
Currently there is no review of Tier 3 services in the UK. This review aims to establish the 
evidence base for Tier 3 WMS for adults, both in hospital and the community, by exploring 
service characteristics, effectiveness and implications for practice. This paper is published as 
a summary of a report commissioned by Public Health England (PHE). Importantly, part of the 
translational work associated with this review involves the development of resources to 
support commissioners and providers of WMS as outlined in the Department of Health’s letter 
detailing PHE’s Strategic Remit and Priorities13. 
Methods 
A protocol (a priori, unpublished) was developed in collaboration with the steering group 
members. The methods are underpinned by the Joanna Briggs Institute (JBI) methodology for 
scoping reviews 14. The template for intervention description and replication (TIDieR) checklist 
and guide were used to extract data on delivery and context15. The review is reported following 
the Preferred Reporting Items for Systematic Reviews guidelines (PRISMA)16.  
Inclusion criteria 
Our background research for this review revealed that there were very few published RCTs of 
Tier 3 WMS for adults in the UK. As such, we took an overarching approach that is used by 
NICE to identify the best available evidence17. Studies of any design that reported outcomes 
at least once pre and once post-intervention were included (RCTs, non-RCTs, and 
uncontrolled before and after studies). Studies with and without comparator groups were 
included without restriction on the type of comparator. 
Adults with a mean baseline BMI of ≥40kg/m2 or ≥35kg/m2 with co-morbidities or ≥30 kg/m2 
with T2DM were included. We applied a mean baseline BMI rather than a cut-off because we 
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were aware of variability and inconsistency in eligibility. Many of the studies identified would 
pre-date the concept and definition of a Tier 3 service. A pragmatic decision was taken to 
include WMS that, although not ‘Tier 3,’ were multicomponent specialist multidisciplinary 
services, where some but not the entire sample had a mean baseline BMI of ≥40 kg/m2. In 
addition, if a study reported outcomes for a subgroup that met our mean baseline BMI criteria, 
although the whole study did not, then the data for the relevant subgroup were extracted.  
Multicomponent interventions comprising diet, physical activity and behaviour change were 
included. The intervention could also include anti-obesity drugs, low-energy liquid diets (LELD) 
or pre/post-bariatric surgery care. Interventions delivered by a MDT including specialists or 
clinicians were included. All study designs of any duration and setting were included. 
Interventions based in the UK or Ireland and published from 2005 onwards were included. 
There was no restriction on the type of outcome data. 
Embase, MEDLINE and PsycINFO were searched from January 2005 to March 2016 and 
articles were retained within a Reference Manager database and further limited to UK-based 
studies using keywords and text words in the abstracts containing ‘England’, ‘Ireland’, 
‘Scotland’, ‘United Kingdom’ or ‘Wales’. Database searches were supplemented by hand 
searches and resources provided by the steering group and study author contacts. Reference 
lists of full-text articles were searched for additional studies. The titles and abstracts were 
screened by one reviewer (TB) who then screened full-text articles. Articles that were unclear 
for inclusion were independently screened by a second reviewer (LE) and a steering group 
member (AA). Articles that remained unclear were referred to PHE for final decision (JB, VC, 
BH).  
Data extraction tables were developed to record participant and study characteristics, 
intervention components and outcomes. Quality appraisals were carried out using the JBI 
appraisal tools18. The studies were subjectively ranked as low (<4/9), moderate (4-6/9) or high 
quality (≥7/9) depending on how many of the quality assessment criteria were met. All data 
were independently extracted by two reviewers (TB, COM); throughout the process a third 
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reviewer (LE) was consulted if any queries arose. Evidence was appraised taking account of 
study design, quality and setting.   
Results 
The searches identified 1913 articles of which 120 were obtained and screened as full-text 
articles. Figure 1 shows the study flow. Grey literature searching, reference list searching and 
contacting authors resulted in the identification of two additional articles. In total, 14 studies 
met the inclusion criteria and were included; 105 articles were excluded of which 11 were 
studies of children which are reported in a separate systematic review (TJ Brown, LJ Ells, C 
O’Malley, et al. – unpublished data). Table 1 shows study characteristics including participant 
baseline characteristics. Supporting information can be found in supplementary tables for:  
detailed characteristics of included studies (Table S1), descriptions of interventions (Table 
S2), quality assessment (Table S3) and additional outcomes (Table S4). 
Characteristics of interventions 
Due to the heterogeneity of the included studies, meta-analyses were not possible, therefore 
a narrative synthesis is provided. 
Study design 
One study was an RCT19. Three studies had a control group (a retrospective case-control 
study20, a prospective nonrandomized trial with a contemporaneous observational control 
group21, and a retrospective non-contemporaneous matched cohort study22). Ten studies were 
uncontrolled, mainly observational cohorts (WMS evaluations) and one was a repeated 
measures cross-sectional study of a WMS23. Two studies had a usual care comparison group.  
Setting and service characteristics 
Seven studies evaluated the impact of existing Tier 3 WMS and one evaluated quality of life 
using participant data from a Tier 3 service23. Four studies were of specialist WMS 
commissioned by Greater Glasgow and Clyde NHS Health Board (GCWMS). One of these 
studies25 adapted the service for adults with intellectual disabilities (TAKE-5).  
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Six studies had similar characteristics to a Tier 3 service; three were hospital-based services 
for adults with T2DM published between 2005 and 200819,20,26. Two evaluated a commercial 
weight management programme, set within primary care27,28. Another hospital-based study 
evaluated a specialist weight management study for patients with chronic kidney disease 
(CKD) who were required to lose weight prior to kidney transplantation21.  
Intervention content 
All interventions were multicomponent including diet, exercise and behaviour change; seven 
studies reported including optional pharmacotherapy. Some studies reported a theoretical 
underpinning of the intervention and training of programme deliverers. There was no evidence 
to suggest user group involvement in the design of the services; one study reported that a 
patient run support group was set up to provide long term support and motivation for 
discharged patients. The studies were too heterogeneous to make further inferences about 
service content. 
Delivery 
The MDT composition varied across the studies; most interventions included a dietitian or 
dietetic assistant, and around half included a physician. The studies were heterogeneous 
making comparisons of delivery difficult, however the majority of studies had a multidisciplinary 
team delivering the services. Table S1 provides further detail of the delivery setup.  
Size and duration 
Studies samples ranged from 28 to 6505 participants. Twelve studies had samples of <850; 
one study had a sample of 3170 and another study had a sample of 6505.  Duration of 
intervention including final follow-up, ranged from 8 weeks to 24 months; six studies 
followed-up participants at 12 months or longer. Table S2 provides detailed description of 
interventions. 
Quality 
Two studies were low quality (<4/9) mainly due to poor reporting of methods, nine studies 
were moderate quality (4-6/9) and three studies were high quality (≥7/9); however none of the 
studies scored more than 7/9. The quality domains that most studies failed to meet were 
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insufficient duration of follow-up and exclusion of dropouts from analyses. Table S3 provides 
detailed quality assessments. 
Participants 
Eligibility criteria for weight in each study varied greatly. Two of the six studies31,32 published 
at the same time or subsequently to the guidelines for Tier 3 WMS7 reported using the 
guideline criteria. Eligibility criteria across ten studies ranged from BMI ≥30 to BMI ≥40 with 
no comorbidities and BMI ≥28 kg/m2 to BMI ≥35 kg/m2 with comorbidities. In two studies (both 
retrospective), eligibility criteria for weight were not reported.  Mean baseline BMI ranged from 
34 kg/m2 to 54 kg/m2. 
Most of the studies included adults with obesity-related comorbidities; two studies recruited 
adults with T2DM26 (participants in one study were on insulin therapy)19. One study recruited 
adults with CKD21. Two studies recruited bariatric patients for specialist WMS prior to 
surgery22,32. One study recruited adults with intellectual disabilities25. 
Mean baseline age ranged from 40 to 58 years. One study included females only20 and 13 
studies included males and females; in eleven of these studies the majority were female ( 55% 
to 81%). Only four studies reported ethnicity; in three of the study samples the majority were 
‘white’ (56% to 99%). In one study21 of adults with CKD, 55% were male, 47% were white, 
40% were black, and 13% were Asian or other ethnicity. Five studies reported area deprivation 
and reported that 34% to 62% of participants were from the most deprived areas. 
Two studies compared the characteristics of adults not recruited with those recruited. Jennings 
et al.30 reported there was no difference in participants who only attended for assessment and 
those who were recruited in terms of gender, baseline weight or BMI. However recruited 
participants were 7.5 years older and reported a better quality of life than participants who only 
attended for assessment. Morrison et al.24 reported that females were more likely than males 
to opt in (73.6% v. 69.4%, respectively; p=0.02) but among those who opted in there was no 
significant difference between the sexes in the proportion who completed the programme. 
Effects of interventions 
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Table 2 provides anthropometric outcome data and Table S4 provides detailed information for 
all reported outcomes. 
Attendance/compliance  
Ten studies reported dropout rates which varied from 13% to 89% by the end of each study 
which ranged from two to 24 months; the majority of the studies had a dropout which ranged 
from 43% to 62% over six to 24 months. The 89% dropout relates to an established Tier 3 
study, which lasted up to 24 months and included three phases of intervention29. Three 
studies19,25,32 had relatively low dropout of between 13% and 20%, and were in carefully 
selected or volunteer samples.  
Two studies compared the characteristics of dropouts with completers. Brown et al.31 reported 
that completers were significantly older (49.2 compared with 46.9 years, p=0.005), had a 
greater prevalence of obstructive sleep apnoea (p=0.0001) and had a greater referral BMI 
(p=0.02). Crowe et al.32 reported that compared to non-completers, completers were older 
(47.9 ± 11.2 versus 40.7 ± 12.9 years, p=0.003), were more likely to be men (34.7 versus 10.3 
%, p=0.008) and were more likely to have diabetes (35.8 versus 13.8 %, p=0.03).  
Two studies reported the effect of attendance on weight loss; Ross et al.28 reported that the 
most favourable weight loss results were seen in adults with high attendance. MacLaughlin et 
al.21 also reported that adults with higher attendance were associated with significantly greater 
weight loss, reduction in BMI and systolic blood pressure (BP) compared to adults with lower 
attendance. 
Anthropometric  
There were no RCTs included in adults without comorbidities. Six studies reported change in 
BMI; with statistically significant change in mean BMI over time ranging from -1.4 kg/m2 to -
3.1 kg/m2.  
Twelve studies (including 1 RCT) reported change in weight; mean change in weight over time 
ranged from -2.2 kg to -12.4 kg. The majority of studies reported a weight loss in the range of 
2 kg to 6 kg. In seven studies the reduction in weight over time was statistically significant.  
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Seven studies reported percentage (%) weight change; change in % weight over time ranged 
from -3.9% to -9.6% for completers, with follow-up ranging from 6 to 24 months.  
Six studies reported clinically significant weight losses of ≥5% initial body weight (IBW) and/or 
≥10% IBW. These six studies included four medium quality and two high quality studies, one 
of which also had the largest sample size assessed (1838 participants). Four of these six 
studies were established Tier 3 services.   
The percentages of adults that completed the weight management programmes and achieved 
≥5% IBW ranged from 32% to 51%. The percentages of adults that completed the weight 
management programmes and achieved ≥10% IBW was approximately 10% at 6 months for 
one lifestyle weight management study31, and 21-22% at 24 months in two other studies that 
included pharmacotherapy29,30. 
Sociodemographic factors as potential effect modifiers 
The evidence was inconsistent for age, baseline BMI, deprivation and sex. Some evidence 
suggested that men, certain age groups, and higher baseline BMI was associated with 
improved weight loss deprivation and diabetes were associated with poorer outcomes. 
Co-morbidities  
One RCT19 in adults with T2DM taking insulin reported statistically significant improvement 
from baseline to 4 months (-2.2 kg for the intervention group and -0.3 kg for control), but this 
was not sustained at 6-month and 12-month follow-ups. The baseline weight varied between 
the groups with the intervention group being nearly 6.5 kg higher than control. The mean 
change in weight was not directly compared between the intervention and control group. In 
one retrospective case-control study20 of lifestyle plus sibutramine versus lifestyle only in 
adults with T2DM, the difference in total weight loss between the two groups was not 
statistically significant at 6 months (-2.32 kg, n=9 vs -1.9 kg, n=9 respectively). 
For adults with T2DM, there is relatively good evidence for significant reductions in HbA1c and 
improvement in glycaemic control, which might be occurring independent of weight loss via 
improvements in diet, physical activity or medication use; this improvement occurred in a 
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variety of settings. Most of the evidence is derived from observational studies; 5 observational 
studies demonstrated significant reductions in HbA1c levels (either in absolute or % values) 
over time in adults with T2DM ranging from -0.6% to -7.6% over various durations (one of 
these studies only showed significant reductions when both the intervention groups with T2DM 
were combined). One observational study showed non-significant reduction in HbA1c levels 
over time and one RCT showed significant decreases in HbA1c levels over time by an average 
of 0.9±1% (p<0.01) in the intervention group, while the control group showed a mean decrease 
of 0.3±0.6% (p<0.05); reductions were not sustained at 6-month and 12-month follow-ups. 
The only study21 to report on longer-term clinical outcomes was specific to adults with CKD; 
patients in the weight management programme had a significantly longer event-free period for 
the combined outcome (all-cause mortality, myocardial infarction, stroke, and hospitalization 
for congestive heart failure), than those in the control group. 
Quality of Life 
There is limited evidence in that only four studies reported on quality of life (1 low, 2 moderate 
and 1 high quality), three of which reported that Tier 3 services significantly improved quality 
of life outcomes, in both community and primary care settings, in both bariatric patients and 
adults with/without comorbidities.   
Behaviour change  
Very few studies reported behaviour change outcomes; it was not possible to ascertain which 
components of the programmes (for example diet and/or physical activity or behaviour change 
techniques) were associated with weight loss. 
Costs 
None of the studies included a cost-effectiveness analysis. Two studies reported costs per 
participant in primary care based services. Lean et al.27 reported costs of £861 per patient 
entered, or £2611 per documented 15 kg loss achieved. Jennings et al.30 reported that a 
primary care based Tier 3 WMS cost between £900 and £1250 per year for each patient.  
Discussion 
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The evidence in this review indicates that specialist MDT services can deliver clinically 
significant weight loss for adults. Due to the majority of evidence being derived from 
observational studies we focus on impact, rather than effectiveness, when describing change 
in outcomes and on the whole this is change from baseline to post intervention. Of note, where 
we report impact, we do so alongside the methodological quality of the study. We appreciate 
that impact results from uncontrolled studies should be treated with caution. The absence of 
a comparison group for the majority of studies makes it impossible to know what would have 
happened without the intervention. Some of the particular problems with interpreting data from 
uncontrolled studies include susceptibility to problems with confounding and regression to the 
mean33.   
All anthropometric outcomes demonstrated significant improvements and support a clinically 
significant weight loss. However, the majority of the studies had a dropout which ranged from 
43% to 62% and most of the evidence derived from observational studies. The one included 
RCT reported a short-term weight reduction over time for the intervention group which was at 
the lower end of the range observed across the other studies (-2.2 kg); however, this study 
was in adults with T2DM on insulin therapy. Impact did not appear to vary by study quality, 
with the high quality studies reporting improvements in anthropometric outcomes across the 
range reported for all studies.  
For adults with T2DM, there is evidence for significant reductions in HbA1c and improvement 
in glycaemic control. Medications for T2DM, particularly insulin, can promote weight gain; 
however the evidence suggests that adults with severe obesity and T2DM can reduce their 
BMI and have a clinically meaningful weight loss. Adults with T2DM have about half the odds 
of significant weight loss and sustainability of weight loss might be harder to achieve for adults 
with T2DM.  
Very few studies reported on Quality of Life or behaviour change outcomes; better reporting 
of these types of outcomes is important to understand other potential beneficial outcomes 
related to WMS and the mechanisms of change underlying anthropometric outcomes. 
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As there were no studies that compared lifestyle intervention with a usual care control for 
severely obese adults, we cannot directly compare the effectiveness of Tier 3 WMS with usual 
care for adults with severe obesity. These types of lifestyle interventions are by their very 
nature, complex interventions; Medical Research Council guidance states that experimental 
designs are preferred to observational designs in most circumstances, but are not always 
practicable and that it is important to also understand processes34. In addition, it is difficult to 
define what ‘usual care’ means given the substantial variation in England’s service provision9.  
It is apparent that NICE have not provided specific guidance on Tier 3 services, perhaps due 
to a lack of evidence evaluating the effectiveness and cost-effectiveness of Tier 3 services 
and a lack of information on the optimum composition of the specialist team. This review 
highlights variation in the composition of the MDT even in established Tier 3 services and it 
was not always clear if providers were specialists in obesity management. The evidence 
suggests there was more likelihood of secondary care or primary care –based studies to have 
physician involvement as part of the MDT compared to community based interventions. None 
of the established services met all the definitions of a Tier 3 service, in terms of BMI eligibility 
criteria, pharmacotherapy for obesity and the composition of a MDT. Even within established 
Tier 3 services only a minority are meeting the suggested composition in the working example 
of what constitutes an MDT3.  This may reflect incomplete or limited reporting within the papers 
or it may reflect actual practice.  
It was not possible to discern which intervention components improved which outcomes as 
most studies lacked a comparator; adding a Tier 3 WMS to Roux-en-Y gastric bypass (RYGB) 
significantly improved %weight loss. Thus supporting the working groups3 patient journey of 
engagement with tier 3 pre and post entry to tier 4.  It was difficult to make further inferences 
about the impact of intervention characteristics on intervention outcomes, given the 
heterogeneity of the interventions and the study designs. Weight loss did not appear to be 
modified by study quality or design or duration of the intervention. The intensity of the 
intervention may affect the amount of weight loss and this requires further exploration. The 
evidence regarding specific sociodemographic factors as potential effect modifiers of weight 
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change was inconsistent. The evidence was also inconsistent regarding the role of gender in 
entering and completing the services; however, the participants in the studies were 
predominantly female. More research is required regarding potential age and gender 
inequality in service access. 
Lower dropout was seen in carefully selected groups of highly motivated adults. There was no 
clear pattern in dropout according to setting. Limited evidence demonstrated the most 
favourable weight loss results in adults with high attendance. When the percentage of 
participants achieving reductions of ≥5% IBW and ≥10% IBW was reported for larger samples 
(not limited to completers only) and the follow-up was at least 12 months, the percentage of 
participants achieving reductions of ≥5% IBW and ≥10% was reduced by about a half.  
Hassan et al.12 recently published a review examining the effectiveness of lifestyle 
interventions for adults with severe obesity. The review included 17 RCTs (none of which were 
based in the UK); participants receiving the lifestyle intervention had a greater decrease in 
weight than participants in the control group for all studies (1.0–11.5 kg). This is similar to the 
range of weight loss found in this review of UK studies of adults with severe obesity; our review 
provides UK evidence albeit derived from less robust study designs. Important issues 
highlighted by Hassan et al.12 included a lack of RCT evidence exclusively targeted at adults 
with a mean BMI >40 kg/m2; by including non-RCT evidence we were able to capture studies 
exclusively targeted at adults with a mean BMI >40 kg/m2. 
Strengths and limitations 
This is the first systematic review of specialist multidisciplinary interventions (Tier 3 WMS) in 
the UK. Review authors believed there would be limited published evidence for Tier 3 services 
and so the scope was kept wide. Hence the review included existing Tier 3 services and other 
specialist multidisciplinary interventions that reflected a Tier 3 service (i.e. a multicomponent 
intervention provided by a multidisciplinary team for severely obese adults). Evidence from 
these types of studies strengthens the evidence base and the applicability of specialist 
multidisciplinary interventions for a wider population of adults with severe obesity. It is 
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important to note therefore that the review identified the best available evidence, and included 
interventions that were not established Tier 3 services and would not meet the NICE CG189 
guidance for Tier 3 services6. Including these studies enabled comparison of services across 
hospital, community and primary care sites; it also enabled evaluation of such services within 
select population groups. 
This review includes evidence from a broad range of study designs and most of the data 
derives from observational studies which limits the inferences that can be made in terms of 
effectiveness. The studies were too heterogeneous to enable meta-analyses; the studies 
varied in terms of design, duration, setting and types of outcomes reported. The main areas 
of concern in terms of study quality were insufficient duration of follow-up and exclusion of 
dropouts from the analyses. 
Although some studies reported on sustainability of weight loss, for example, reporting longer-
term follow-up data, there were no data that reported immediately after an active intervention 
phase and then reported data again following a period of no action or a maintenance phase. 
Therefore we do not know if weight reductions are sustained in the longer-term after 
completion of treatment. 
It was often difficult to ascertain on screening of references for inclusion, which of the 
community based studies were specialist multidisciplinary interventions (Tier 3) and which 
were lifestyle interventions (Tier 2). This was mainly due to insufficient information being 
provided about who was delivering the service. 
Implications for practice 
Tier 2 and 3 service user populations cannot be directly compared, as tier 3 users are likely to 
be complex patients with multiple medical and psychological problems. Tier 3 services are 
likely to have higher staff costs but deliver a service that includes medical assessment and 
more specialist care given the more severe and/or complex nature of obesity, and/or co-
morbidities in these patients. There is a need to clarify composition of MDTs to ensure the 
complex needs of patients entering a Tier 3 service are met. Services should meet defined 
 16 
 
eligibility criteria to ensure equitable provision across the country, and alignment with NICE 
recommendations and Tier 2 and Tier 4 provision. Comparison across services could be 
improved by applying a clinical scoring system such as the Edmonton Obesity Scoring System 
(EOSS)35,36. 
There is a need for standardised key performance indicators for all Tier 3 services. Services 
should be encouraged to use the standard evaluation framework8, to improve consistency in 
reporting and ensure important data such as sociodemographics, dropout rates and longer 
term outcomes are collected. Stipulating set time points and success criteria would help 
facilitate comparisons between services. Services should report findings for all patients as well 
as for completers. Services should record reduction in comorbidities and metabolic 
parameters to examine wider possible health benefits. It is important services undertake 
appropriate process and impact evaluations to help understand which elements work and don’t 
work, for whom and why. This should include clear details of how different components are 
delivered. Cost-effectiveness data must be collected and reported, particularly when there is 
evidence of effectiveness.  
Future services must consider consulting with end users to ensure services are equitable: 
meeting the needs of all users e.g. men, younger patients, and working patients. Assessing 
motivation to change is recommended, as evidence suggests attrition rates are lower in 
carefully selected groups of highly motivated adults.  
Implications for research 
Future research of specialist multidisciplinary interventions needs to ensure important 
mediators and moderators such as sociodemographic factors are measured and analysed. 
Research studies should consider aligning with the standard evaluation framework, to enable 
comparison of outcomes across studies. More research is required to examine the 
effectiveness of specialist multidisciplinary intervention provision for minority ethnic groups, 
younger adults and adults referred to the service from bariatric surgery (Tier 4). More research 
is required to examine the impact of intensity and different programme components in 
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specialist multidisciplinary interventions. Future studies should consider using RCT designs 
where possible and all studies should clearly report the service content and delivery. 
Conclusions 
Evidence demonstrates that multicomponent weight management interventions provided by 
multidisciplinary teams can have a positive clinically significant impact for adults with severe 
and often complex forms of obesity. The review provides evidence to support the provision 
of Tier 3 services for adults and highlights important variations in Tier 3 provision across the 
UK, and the need for services that are accessible to and used by all populations in need.  
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Table 1 Summary of included study characteristics 
Author, year Study design Setting  Interventions Mean age, 
years (sd) 
Mean baseline BMI 
kg/m2 (sd)  
Female 
(%) 
Barratt 200821 Retrospective case 
control 
H Dietitian-led lifestyle (diabetic)  48.89 (8.72) 43.78 (13.56) 100 
Dietitian-led sibutramine + lifestyle (diabetic) 43.67 (11.84) 41.11 (6.93) 100 
Dietitian-led sibutramine + lifestyle (nondiabetic) 40.40 (8.88) 40.04 (7.50) 100 
*Brown 201532 BA no control H Specialist Lifestyle Management  48.2 (11.6) 49.8 (9.3) 74 
Cheyette 200720 RCT H Dietitian led weight management for T2DM 
taking insulin 
56.7 (9.7) 
 
34.1 (4.7) 
 
52 
Usual care for diabetics 58.0 (10.7) 31.7 (5.3) 40 
*Crowe 201533 Retrospective cohort COM Lifestyle programme for bariatric patients 47.9 (11.3) 46.3 (8.3) 65 
*Jennings 
201431 
BA no control GP Tier 3 weight management including orlistat 52.7 (13.6) 44.1 (7.8) 70 
Lean 201328 Feasibility BA no 
control 
GP LELD (reintroduction/maintenance/optional 
Orlistat) 
46 48.0 (7.6) 
 
81 
*Logue 201430 BA no control COM Specialist weight management including orlistat M: 51.9 (11.96)  
F: 48.1 (13.86) 
43.26 (NR) 73 
MacLaughlin 
201522 
CCT H Renal weight management including Orlistat 52.3 (12.9) 36.6 (5.3) 49 
Usual care control 53.3 (12.7) 34.5 (5.1) 42 
*Melville 201126 BA no control HO Specialist intellectual disability dietetic service 48·3 (12·01 40·0 (8·03) 59 
*Morrison 201225 BA no control H + 
COM 
Specialist weight management  M: 47.5 
F: 44.6 
41**  
*Patel 201523 Retrospective matched 
cohort 
H Tier 3 + RYGB 46.5 54.1 (9.4) 76 
RYGB 44 53.2 (11.2) 68 
Ross 200829 BA no control GP Counterweight  49.4 (13.5 25% = BMI ≥40 77 
Rowe 200527 BA no control H Diabetic weight management with Orlistat M: 54.5 (10.8)  
F: 54.8 (11.6) 
39.5 (6.5) 55 
*Wright 201324 Cross-sectional COM Specialist weight management  49.7 (12.6) 42.32** 76 
Legend, Table 1: *established Tier 3 service; ** reviewer calculated; BA: observational before-after study;  BMI: body mass index;  C: control group (usual care); CCT: 
controlled clinical trial; C/I: CKD: chronic kidney disease; COM: community; F: female; GP: general practice; H: hospital; HO: home; I: intervention group; LD: Lifestyle diabetic 
group; LELD: low-energy liquid diet; M: male; NR: not reported; RCT: randomised controlled trial; RYGB: Roux-en-Y gastric bypass; sd: standard deviation; SID: Sibutramine + 
lifestyle diabetic group;  SIO: Sibutramine + lifestyle nondiabetic group; T2DM: type 2 diabetes mellitus 
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Table 2 Anthropometric outcomes   
Intervention Body Mass 
Index (kg/m2) 
Weight (kg) 
Study 
Summary 
Group  No.  Duration 
(months)  
 
Mean change 
from baseline  
(sd/95% CI) 
Mean change 
from baseline  
(sd/95% CI) 
Mean % change 
from baseline 
(sd/95% CI) 
% pts ≥5% 
IBW 
 
% pts 
≥10% IBW 
 
Barratt 200821 
SID vs LD = NS, did not 
directly compare 
nondiabetic group (SIO) 
with diabetics groups 
(SID/LD), statistical 
significance from baseline 
to follow-up not clear 
Sibutramine 
+ lifestyle 
nondiabetic 
(SIO) 
Assessed:  
n=10 
 
 
6 -4.07 (2.98) 
 
 
-10.74 (7.49) 
 
 
-9.66% (1.74) 
 
80%, 8/10 NR 
Sibutramine 
+ lifestyle 
diabetic 
(SID) 
Assessed:  
n=9 
-2.32 (1.12) 
 
-6.36 (3.10) 
 
-5.81% (0.91) 66%, 6/9  
Lifestyle 
diabetic (LD)  
Assessed:  
n=9 
-1.9 (1.20) -5.26 (3.53) -4.54%  
(0.94) 
44.4%, 4/9  
Brown 201532 
 
Statistically significant 
improvement from 
baseline to follow-up 
Specialist 
Lifestyle 
Management  
Programme 
(SLiM) 
Enrolled: 
828 
Assessed: 
424 
 
6 3 months: 
-1.3 (2.1), n=404 
6 months: 
-2.0 (2.8), 
n=464; 
6 months: 
-1.48 (-1.3 to -
1.7), n=828;  
3 months: 
-3.7 (5.4), n=404 
6 months: 
-5.5 (7.4), n=464; 
6 months: 
-4.1 (-3.1 to -4.0), 
n = 828;  
6 months: 
3.9% (5%), n=464 
6 months: 2.9% 
(4.9%), n=828 
 
6 months: 
32.3%, 
n=464, 
24.9%, 
n=828 
 
6 months: 
7.7%, 
n=828 
6 
months:10
%,approx.  
from figure,  
n=464  
Subset 
diabetics 
enrolled/as
sessed: 
266/142 
 6 months: 
-1.2 (8.9),  
-5.7 (6.9) -4.0 % (4.57%) 30%  11%  
Cheyette 200720 
 
Mean difference between 
groups not reported 
(intervention group 6.5 kg 
heavier at baseline than 
control), 
Statistically significant 
improvement from 
Dietitian led, 
weight 
management 
programme 
for T2DM 
taking insulin 
Randomise
d: 29  
Assessed: 
21 
12 NR 4 months:-2.2 
(2.7), n=29 
12 months: 0.0 
(NR), n=21, NS 
from baseline 
NR NR NR 
Usual care Randomise
d: 20 
NR 4 months: -0.3 
(NR) 
NR NR NR 
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Intervention Body Mass 
Index (kg/m2) 
Weight (kg) 
Study 
Summary 
Group  No.  Duration 
(months)  
 
Mean change 
from baseline  
(sd/95% CI) 
Mean change 
from baseline  
(sd/95% CI) 
Mean % change 
from baseline 
(sd/95% CI) 
% pts ≥5% 
IBW 
 
% pts 
≥10% IBW 
 
baseline to 4 months not 
sustained at 6-month and 
12-month follow-ups 
Assessed: 
18 
6 months: +1.1 
(NR), n=18, NS 
from baseline 
Crowe 201533 
Statistically significant 
improvement from 
baseline to 2 month 
follow-up  
Lifestyle 
programme 
for bariatric 
patients 
Enrolled: 
183 
Assessed: 
150 
2 -1.4 (-2.1 to -
0.7) 
 
-2.7 (-3.4 to -2.0) 
 
NR NR NR 
 
 
 
 
 
Jennings 201431 
Statistically significant 
improvements in weight 
from baseline to each 
follow-up for completers, 
those with recorded 
weight and BOCF except 
BOCF at final 24-mnth 
follow-up 
Tier 3 weight 
management 
including 
orlistat 
Recruited: 
230 
Assessed: 
230 
 
24 NR 
 
3 months: -3.4 
(3.9), n=230 
6 months: -4.0 
(5.6), n=230 
9 months: -5.5 
(6.8), n=230 
12 months: -5.9 
(7.8), n=230 
18 months: 
-4.7 (9.7), n=157 
24 months:  
-2.6 (7.4), n=84 
24 months: 
-2.3% (6.3%), 
n=84 
 
24 months:  
-5.1% (9.1%), 
n=29 
24 months: 
23.9% 
(20/84) 
 
24 months: 
44.8% 
(13/29) 
24 months: 
10.7% 
(9/84) 
 
24 months: 
20.7% 
(6/29) 
BMI≥40 
subgroup, 
n=155 
-3.1 (NR) 3 months: -4.3 
(4.2), n=152 
6 months: -6.9 
(5.9), n=134 
9 months: -9.0 
(7.4), n=102 
12 months: -9.3 
(8.7), n=116 
   
Lean 201328 
Statistically significance 
from baseline to follow-up 
LELD 
(reintroductio
n/maintenanc
Entered: 91 
Assessed: 
91 
12 NR 
 
-12.4 (11.4)  -9.1% (8.2%) NR NR 
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Intervention Body Mass 
Index (kg/m2) 
Weight (kg) 
Study 
Summary 
Group  No.  Duration 
(months)  
 
Mean change 
from baseline  
(sd/95% CI) 
Mean change 
from baseline  
(sd/95% CI) 
Mean % change 
from baseline 
(sd/95% CI) 
% pts ≥5% 
IBW 
 
% pts 
≥10% IBW 
 
not reported as not 
powered  
e/optional 
Orlistat) 
Logue 201430  
Statistically significant 
improvement from 
baseline to follow-up 
Specialist 
weight 
management 
including 
orlistat 
Referred: 
6505 
Eligible: 
5637 
Assessed: 
1838 
(LOCF) 
Up to 24 
months 
(end of 
phase 3 = 
19 months) 
NR 3 months:  
-2.7 (-2.9 to -2.5)  
6 months:  
-3.4 (-3.6 to -3.2)  
12 months:  
-3.6 (-3.9 to -3.3)  
18-24 months:  
-3.56 (-3.8 to -3.3)  
NR 12 months: 
24%, 
n=447/1838 
 
12 months: 
51%, 
n=203/399 
NR 
Subgroup 
Baseline 
BMI 40-49: 
7 months 
(end of 
phase 2) 
NR -4.32 (-5.1 to -3.5) 
n=242 males; -
3.49 (-3.9 to -3.1) 
n=630 female; 
NR NR NR 
Subgroup 
BMI ≥50: 
7 months 
(end of 
phase 2) 
NR -5.97 (-8.1 to -3.9) 
n=80 male; -3.93 
(-4.8 to -3.1) 
n=209 female 
NR NR NR 
MacLaughlin 201522 
statistically significant 
difference between 
groups for weight at 12 
months, statistically 
significant improvement 
from baseline to 24-
months for BMI and % 
weight for intervention 
group 
Renal weight 
management 
programme 
including 
Orlistat 
 
Referred: 
369 
Recruited: 
185  
Assessed: 
169 
24 24 months: 
I: -1.5 (0.2), 
n=135 
 
12 months: 
-4.3 (5.5), n=169 
 
24 months: 
-4.0% (0.5), 
n=135 
 
24 
months:42.7
%, n=135 
 
24 months: 
22.1%, 
n=135 
 
usual-care 
control 
Declined 
and 
became 
C:175 
Assessed: 
169 
 NR 12 months: 
-1.9 (6.6) 
NR NR NR 
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Intervention Body Mass 
Index (kg/m2) 
Weight (kg) 
Study 
Summary 
Group  No.  Duration 
(months)  
 
Mean change 
from baseline  
(sd/95% CI) 
Mean change 
from baseline  
(sd/95% CI) 
Mean % change 
from baseline 
(sd/95% CI) 
% pts ≥5% 
IBW 
 
% pts 
≥10% IBW 
 
Melville 201126 
Statistically significant 
improvement from 
baseline to follow-up 
TAKE 5 
specialist 
intellectual 
disability 
dietetic 
service 
Invited: 101 
Participated
: 54 
Assessed: 
47 
6 -1·82  
(-2·36 to -1·29)  
-4·47  
(-5·91 to -3·03) 
NR 36·2%, n=47 NR 
Morrison 201225 
Statistical significance not 
reported 
Specialist 
weight 
management 
Referred: 
3170 
Assessed: 
2976 
4 NR NR 
 
NR NR NR 
Patel 201523 
Statistically significant 
difference between 
groups for % weight 
change at 6 and 12 
months 
 
 
Tier 3+RYGB  
 
I1: 44 
I2: 66 
12 NR NR 6 months: -31% 
(0.10) 
 
12 months: 
-34% (0.09) 
NR NR 
RYGB  NR NR 6 months:-23% 
(0.12) 
 
12 months: 
-27% (0.87) 
NR NR 
Ross 200829 
Statistically significant 
improvement in weight 
from baseline to follow-up 
Counterweig
ht 
Subgroup 
(25%) with 
BMI ≥40 
n=160 
12 NR 
 
 
–4.60 (8.86/–5.98 
to –3.22) 
NR NR NR 
Rowe 200527 
Statistically significant 
improvement from 
baseline to 6-month 
follow-up 
Diabetic 
weight 
management 
with Orlistat 
Recruited: 
100 
Assessed: 
82 
24 NR 6 months:  
-7.1 (NR) 
6 months:  
-6.2% (4.0%) 
 
6 months:  
51.2% 
NR 
Wright 201224 Specialist 
weight 
management  
Attended 
≥4 closed 
group 
4.5 NR -5.1 (4.3) NR NR NR 
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Intervention Body Mass 
Index (kg/m2) 
Weight (kg) 
Study 
Summary 
Group  No.  Duration 
(months)  
 
Mean change 
from baseline  
(sd/95% CI) 
Mean change 
from baseline  
(sd/95% CI) 
Mean % change 
from baseline 
(sd/95% CI) 
% pts ≥5% 
IBW 
 
% pts 
≥10% IBW 
 
Statistically significant 
improvement from 
baseline to follow-up 
sessions: 
n=199 
Legend, Table 2: BOCF: baseline observation carried forward; CI: confidence interval; IBW: initial body weight; LD: Lifestyle diabetic group; LELD: low energy liquid diet; 
LOCF: last observation carried forward; NR: not reported; NS: not significant; RYGB: Roux-en-Y gastric bypass; SIO: sibutramine + lifestyle nondiabetic group; SID: 
sibutramine + lifestyle diabetic group; SD: standard deviation; T2DM: type 2 diabetes mellitus
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Tables and figure legends  
 
Table 1: *established Tier 3 service; ** reviewer calculated; BA: observational before-after 
study;  BMI: body mass index;  C: control group (usual care); CCT: controlled clinical trial; 
C/I: CKD: chronic kidney disease; COM: community; F: female; GP: general practice; H: 
hospital; HO: home; I: intervention group; LD: Lifestyle diabetic group; LELD: low-energy 
liquid diet; M: male; NR: not reported; RCT: randomised controlled trial; RYGB: Roux-en-Y 
gastric bypass; sd: standard deviation; SID: Sibutramine + lifestyle diabetic group;  SIO: 
Sibutramine + lifestyle nondiabetic group; T2DM: type 2 diabetes mellitus 
 
Table 2: BOCF: baseline observation carried forward; CI: confidence interval; IBW: initial 
body weight; LD: Lifestyle diabetic group; LELD: low energy liquid diet; LOCF: last 
observation carried forward; NR: not reported; NS: not significant; RYGB: Roux-en-Y gastric 
bypass; SIO: sibutramine + lifestyle nondiabetic group; SID: sibutramine + lifestyle diabetic 
group; SD: standard deviation; T2DM: type 2 diabetes mellitus 
 
